Sanofi (France)
NEWS
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.
Sanofi will more than $1 billion to build out its mRNA facilities and programs over the next several years. The site is expected to become operational in 2025.
Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
JOBS
IN THE PRESS